Aktuellt
SENASTE
Besides starting its third proprietary development project in Q2 (NEX-22, a long-acting formulation of liraglutide for treatment of type 2 diabetes), Nanexa has also picked up pace in signing new PharmaShell platform evaluation agreements, with two new deals in the last couple of months. With the start of phase I with NEX-20 in Q4’22 (a long-acting injectable of lenalidomide for treatment of multiple myeloma), and phase I with NEX-22 and NEX-18 (long-acting injectable azacitidine for myelodysplastic syndrome) in 2023, we expect an eventful year ahead. We now find support for fair value of SEK 6.6-8.1 per share, before adjustment for a likely capital raise which is drawing closer.
LÄS MER
